Sonia Zúñiga
Virologist at the National Biotechnology Centre (CNB-CSIC)
We will have to wait and see how and when this measure is implemented. It makes sense in the most vulnerable population, but it remains to be seen whether it will be of benefit to the rest of the population. At the moment it does not seem that the usefulness of a fourth dose in the whole population will be very high, given that people are already protected from severe disease, as shown by the current constant numbers of hospitalisations and ICU admissions.
Another aspect that will have to be considered and implemented is that, from Christmas until now, the circulation of the virus is very high and there are many infections (many of them in people already vaccinated) that involve mild symptoms, but that make these people acquire the so-called hybrid immunity, more complete than the one they had before infection, so it would not make much sense to give them a fourth dose in the autumn-winter. The problem is that these individuals, in many cases diagnosed with antigen self-testing, are not being counted and this information does not appear in the medical records of these people, which could hinder the vaccination strategy.